To address this gap, we developed a robust protocol to create patient-derived organoid cultures from TAFs and cancer cells separately obtained from primary malignant ER+ human breast tumors as well as from NAFs obtained from the normal breast tissues. This evidence concerns the gene ESR1 and breast neoplasm.